Table 4.
Demographics, Past Medical History, and Laboratory Studies
| Use of Warfarin at Baseline | No OAC at Baseline | |||||
|---|---|---|---|---|---|---|
| Not Switched to Dabigatran (n=6122) | Switched to Dabigatran (n=532) | P Value | Not Switched to Dabigatran (n=1956) | Switched to Dabigatran (n=184) | P Value | |
| Age, y | 76 (68 to 82) | 73 (64 to 80) | <0.0001 | 74 (64 to 82) | 68 (62 to 80) | 0.005 |
| Female | 43 | 41 | 0.4 | 43 | 41 | 0.5 |
| Race | ||||||
| White | 89 | 94 | 0.002 | 89 | 90 | 0.9 |
| Black or African American | 4.7 | 2.8 | 5.1 | 4.4 | ||
| Hispanic | 4.5 | 1.7 | 3.6 | 3.8 | ||
| Other | 1.3 | 1.9 | 1.7 | 1.1 | ||
| Health insurance status | ||||||
| Medicare or Medicaid | 73 | 66 | 0.001 | 65 | 55 | 0.01 |
| Private | 22 | 29 | 30 | 40 | ||
| Other | 4.5 | 5.1 | 5.3 | 4.9 | ||
| Hypertension | 85 | 84 | 0.4 | 78 | 79 | 0.7 |
| Hyperlipidemia | 74 | 72 | 0.3 | 69 | 65 | 0.3 |
| Diabetes | 31 | 24 | 0.002 | 26 | 25 | 0.8 |
| COPD | 17 | 14 | 0.1 | 17 | 13 | 0.2 |
| Osteoporosis | 14 | 13 | 0.5 | 14 | 10 | 0.2 |
| Prior gastrointestinal bleeding | 8.2 | 7.3 | 0.5 | 13 | 7.1 | 0.01 |
| Cognitive impairment or dementia | 2.5 | 3.8 | 0.09 | 3.7 | 1.7 | 0.1 |
| Frailty | 5.2 | 4.1 | 0.3 | 8.2 | 2.7 | 0.007 |
| BMI, kg/m2 | 29 (26 to 34) | 29 (26 to 35) | 0.3 | 28 (25 to 33) | 30 (26 to 36) | 0.0002 |
| Hemoglobin, g/dL | 13.5 (12.3 to 14.6) | 13.7 (12.6 to 14.8) | 0.004 | 13.4 (12.1 to 14.5) | 13.7 (12.5 to 14.9) | 0.03 |
| Calculated creatinine clearance*, mL/min per 1.73 m2 | 69 (50 to 94) | 77 (55 to 101) | <0.0001 | 69 (48 to 99) | 77 (59 to 107) | 0.003 |
Values are presented as % or median (IQR). BMI indicates body mass index; COPD, chronic obstructive pulmonary disease; OAC, oral anticoagulant.
*
As calculated by the Cockcroft‐Gault formula.